Medical Condition News

RSS

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Findings could have important implications for personalized treatment of colon cancer

A common observation in oncology is the phenomenon that a patient with a tumor receives a drug and responds very well, but after a few months the cancer comes back and is now resistant to previously administered chemotherapy. What happened? Many mechanisms contribute to explain this effect called "acquired resistance", but today the group Manel Esteller, Director of Epigenetics and Cancer Biology at the Bellvitge Biomedical Research Institute, ICREA researcher and Professor of Genetics at the University of Barcelona, describes in the official Journal of the National Cancer Research Center in the United States, The Journal of The National Cancer Institute, the existence of epigenetic differences that explain the lack of response of the tumor recurs.

4 Dec 2013

New book provides advice on how to engage and motivate adults with cognitive disorders

The Lewy Body Dementia Association is partnering with R.O.S. Therapy Systems, the company that created the first and only activity system for older adults with physical and cognitive disorders, to help create awareness of Lewy Body Dementia and help family caregivers by introducing them to Activities 101 for the Family Caregiver.

4 Dec 2013

Research findings pave new ways to treat gastrointestinal disorders

For those living with gastrointestinal disorders, such as ulcers or Crohn's disease, treatment often means quelling uncomfortable symptoms through medications or dietary changes. But what if one day treatment meant doing away with the old gut for a new gut free of inflamed or diseased tissues?

4 Dec 2013

Cognitive behavioral therapy for PTSD affects underlying biology of the disorder

A new paper published in Biological Psychiatry suggests that cognitive behavioral therapy for posttraumatic stress disorder not only reduces symptoms but also affects the underlying biology of this disorder.

4 Dec 2013

Young athletes are more prone to hip impingement, say specialists

Hip pain is no longer reserved for older adults. More and more young, active people are developing this problem, which often requires surgery to repair.

4 Dec 2013

A new approach for treating colorectal cancer

Scientists and surgeons at Princess Margaret Cancer Centre have discovered a promising new approach to treating colorectal cancer by disarming the gene that drives self-renewal in stem cells that are the root cause of disease, resistance to treatment and relapse.

4 Dec 2013

Scientists receive $12.5M NIH grant to continue research on targeted therapies for melanoma

Despite recent advances in therapy, melanoma remains the deadliest, most aggressive form of skin cancer as incidence rates continue to climb. Now, a team of melanoma scientists from The Wistar Institute and the University of Pennsylvania received a $12.5 M, five-year program project grant (P01) from the National Institutes of Health to continue trailblazing research on targeted therapies in melanoma.

4 Dec 2013

Mount Sinai cardiologists contribute to the creation of new cardiomyopathy classification system

Leading cardiologists at The Mount Sinai Hospital have contributed to the development of a new classification system called MOGE(S) for cardiomyopathies, the diseases of the heart muscle which can lead to heart enlargement and heart failure.

4 Dec 2013

New research suggests that Alzheimer's gene may begin to affect brains in childhood

People who carry a high-risk gene for Alzheimer's disease show changes in their brains beginning in childhood, decades before the illness appears, new research from the Centre for Addiction and Mental Health suggests.

3 Dec 2013

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

For some, the disease multiple sclerosis attacks its victims slowly and progressively over a period of many years. For others, it strikes without warning in fits and starts. But all patients share one thing in common: the disease had long been present in their nervous systems, hiding under the radar from even the most sophisticated detection methods. But now, scientists at the Gladstone Institutes have devised a new molecular sensor that can detect MS at its earliest stages-even before the onset of physical signs.

3 Dec 2013

Scientists identify enzyme that could lead to better treatment of Alzheimer's disease

St. Jude Children's Research Hospital scientists have identified an enzyme that can halt or possibly even reverse the build-up of toxic protein fragments known as plaques in the brains of mice with Alzheimer's disease. The research appeared in a recent edition of the scientific journal Nature Communications.

3 Dec 2013

Exercise may benefit older people with dementia

Exercise may benefit older people with dementia by improving their cognitive functioning and ability to carry out everyday activities, according to a new systematic review published in The Cochrane Library. However, the authors of the review did not see any clear effect of exercise on depression in older people with dementia and say that more evidence is needed to understand how exercise could reduce the burden on family caregivers and health systems.

3 Dec 2013

U.S. physicians use CSI's Diamondback 360 Coronary OAS for coronary artery disease treatment

Cardiovascular Systems, Inc., today announced that its new Diamondback 360 Coronary Orbital Atherectomy System is being used by physicians across the country to treat coronary artery disease. This follows the company's recent PMA approval from the U.S. Food and Drug Administration to market the device as a treatment for severely calcified coronary arteries.

3 Dec 2013

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

Researchers at MIT and Brigham and Women's Hospital have shown that they can grow unlimited quantities of intestinal stem cells, then stimulate them to develop into nearly pure populations of different types of mature intestinal cells. Using these cells, scientists could develop and test new drugs to treat diseases such as ulcerative colitis.

3 Dec 2013

FDA clears Cochlear Baha 4 Attract System for use in the U.S.

Cochlear Limited, the global leader in implantable hearing solutions, announced that the US Food and Drug Administration cleared the Cochlear Baha 4 Attract System for use in the United States. Cochlear is the only company to now offer patients a choice of either a magnetic or a direct bone conduction hearing solution.

3 Dec 2013

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

Patient Engagement Systems, a nationally recognized leader in developing technology to identify, and monitor individuals with chronic kidney disease, today introduced the Patient Engagement Systems' ESRD Prevention Program which uses proprietary technology including automated physician-patient engagement, analytics, and decision support tools to identify patients with undiagnosed chronic kidney disease and tools to monitor them in order to prevent or delay the progression to ESRD.

3 Dec 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.

3 Dec 2013

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

3 Dec 2013

Study supports use of EndoBarrier Therapy for patients with type 2 diabetes and obesity

GI Dynamics, Inc. today announced findings from a new meta-analysis which describes the increasingly robust efficacy and safety profile of EndoBarrier Therapy, an endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity.

3 Dec 2013

Medical Condition News

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

Findings could have important implications for personalized treatment of colon cancer

New book provides advice on how to engage and motivate adults with cognitive disorders

Research findings pave new ways to treat gastrointestinal disorders

Cognitive behavioral therapy for PTSD affects underlying biology of the disorder

Young athletes are more prone to hip impingement, say specialists

A new approach for treating colorectal cancer

Scientists receive $12.5M NIH grant to continue research on targeted therapies for melanoma

Mount Sinai cardiologists contribute to the creation of new cardiomyopathy classification system

New research suggests that Alzheimer's gene may begin to affect brains in childhood

Gladstone scientist devise new molecular sensor that can detect MS at earliest stages

Scientists identify enzyme that could lead to better treatment of Alzheimer's disease

Exercise may benefit older people with dementia

U.S. physicians use CSI's Diamondback 360 Coronary OAS for coronary artery disease treatment

Researchers find way to replace Paneth cells with two small molecules that maintain stem cells

FDA clears Cochlear Baha 4 Attract System for use in the U.S.

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Study supports use of EndoBarrier Therapy for patients with type 2 diabetes and obesity

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News